100 million doses of the new crown test vaccine! Johnson and Johnson reached an agreement with the U.S. government.

Guide: Under the subsequent agreement, the U.S. government could also buy an additional 200 million doses of Ad26.COV2.S.
Johnson and Johnson announced today that its Johnson and Johnson Pharmaceuticals has reached an agreement with the U.S. government to mass produce and supply 100 million doses of Jansen's new generic virus experimental vaccine, Ad26.COV2, in the United States.
may be used in the United States with approval from the U.S. Food and Drug Administration (FDA) or an emergency use authorization.
the U.S. Department of Health and Human Services Office of The Assistant Secretary for Defense and Response, the Office of The Department of Health and Human Services, a division of the Biomedical Advanced Research and Development Authority ,"BARDA" and will invest more than $1 billion in the agreement.
vaccine will be available worldwide in a non-profit format for emergency outbreaks.
the U.S. government could also buy an additional 200 million doses of Ad26.COV2.S under a subsequent agreement. "Johnson and Johnson's global team of experts has been working tirelessly with BARDA and its research partners to develop a new coronavirus vaccine that will help stop the spread of new coronal pneumonia," said Paul Stoffels, M.D., vice chairman and chief scientific officer of
Johnson and Johnson.
We are very grateful to the U.S. government for its confidence and support in our research and development platform and efforts, as well as for the scalability of our vaccine technology.
we are expanding production in the U.S. and around the world to provide emergency vaccines for new coronavirus vaccines" under the supervision of the U.S. Food and Drug Administration, Johnson and Johnson is working with BARDA on research and development efforts to develop a new coronavirus vaccine.
is conducting the first human trial of vaccine candidate Ad26.COV2.S in the first phase of a human trial in the United States and Belgium, based on positive preclinical data recently published in the peer-reviewed journal Nature.
the company is evaluating one and two doses in clinical projects and working to ensure that the vaccine is available globally with regulatory approval or authorization.
Johnson and Johnson aims to achieve its goal of delivering more than 1 billion doses of vaccine worldwide by 2021, while it is safe and effective.
Johnson and Johnson's new coronavirus vaccine program uses Jansen's AdVac ® technology.
the technology has been used to develop an Ebola vaccine approved by the European Commission and to build a candidate vaccine for HIV, RSV (respiratory syncytial virus) and Zika virus.
so far, more than 90,000 people have been vaccinated on the Janssen AdVac ® platform.
.